Results for &quot;&quot;Probenecid&quot;&quot;[mesh_terms]

Gout - An update of aetiology, genetics, co-morbidities and management.

Philip C Robinson

Maturitas 2019;118():67-73

Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.

Damayanthi Devineni, Nicole Vaccaro, Joe Murphy, Christopher Curtin, Rao N V S Mamidi, Sveta Weiner, Shean-Sheng Wang, Jay Ariyawansa, Hans Stieltjes, Ewa Wajs, Nicholas A Di Prospero, Paul Rothenberg

International journal of clinical pharmacology and therapeutics 2015;53(2):115-28

Treating difficult crystal pyrophosphate dihydrate deposition disease.

Nadia Announ, Pierre-André Guerne

Current rheumatology reports 2008;10(3):228-34

Active renal secretion of NXY-059, a novel neuroprotectant, is mediated via an organic acid transporter.

Yi-Fang Cheng, Stig Strid, Olof Borgå, Dag Nilsson, Johan Wemer

Journal of clinical pharmacology 2007;47(7):909-14

Exploratory Application of Neuropharmacometabolomics in Severe Childhood Traumatic Brain Injury.

Robert S B Clark, Michael J Bell, Patrick M Kochanek, Philip E Empey, Hülya Bayir, Samuel M Poloyac, Xiaochao Ma, Pengcheng Wang, Fanuel T Hagos

Critical care medicine 2019;46(9):1471-1479

Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters.

Aleksandra Galetin, Amin Rostami-Hodjegan, Jan Snoeys, Frank Jacobs, Annett Kunze, Kayode Ogungbenro, Amais Ahmad

CPT: pharmacometrics & systems pharmacology 2022;10(5):467-477

Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

James T Dalton, Christopher C Coss, Amanda Jones

Investigational new drugs 2017;34(4):458-67

Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.

Regina Sennewald, Sreeraj Macha, Rüdiger Koenen, Katja Schöne, Noemi Hummel, Stephan Riedmaier, Hans J Woerle, Afshin Salsali, Uli C Broedl

Clinical therapeutics 2014;36(2):280-90.e1

Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.

Norio Yasui-Furukori, Tsukasa Uno, Kazunobu Sugawara, Tomonori Tateishi

Clinical pharmacology and therapeutics 2005;77(1):17-23

Pharmacological treatment in calcinosis cutis associated with connective-tissue diseases.

Alina Dima, P Balanescu, C Baicus

Romanian journal of internal medicine = Revue roumaine de medecine interne 2014;52(2):55-67

Invasive sinonasal actinomycosis: case report and literature review.

Nopawan Vorasubin, Arthur W Wu, Christina Day, Jeffrey D Suh

The Laryngoscope 2013;123(2):334-8

A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.

Matthew G Fury, Lee M Krug, Christopher G Azzoli, Sunil Sharma, Nancy Kemeny, Nian Wu, Mark G Kris, Naiyer A Rizvi

Cancer chemotherapy and pharmacology 2006;57(5):671-7

Effect of pharmacological lowering of plasma urate on exercise-induced oxidative stress.

S R McAnulty, P A Hosick, L S McAnulty, J C Quindry, L Still, M B Hudson, A N Dibarnardi, G L Milne, J D Morrow, M D Austin

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme 2008;32(6):1148-55

Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans.

Kazuya Maeda, Ying Tian, Tomoe Fujita, Yasuhiko Ikeda, Yuji Kumagai, Tsunenori Kondo, Kazunari Tanabe, Hideki Nakayama, Shigeru Horita, Hiroyuki Kusuhara, Yuichi Sugiyama

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2015;59():94-103